138 related articles for article (PubMed ID: 24976294)
1. Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells.
Tian A; Wilson GS; Lie S; Wu G; Hu Z; Hebbard L; Duan W; George J; Qiao L
Cancer Lett; 2014 Sep; 351(2):232-41. PubMed ID: 24976294
[TBL] [Abstract][Full Text] [Related]
2. LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
Yang C; Wang H; Zhang B; Chen Y; Zhang Y; Sun X; Xiao G; Nan K; Ren H; Qin S
J Exp Clin Cancer Res; 2016 Sep; 35(1):158. PubMed ID: 27737687
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells.
Chen KF; Lin JP; Shiau CW; Tai WT; Liu CY; Yu HC; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Aug; 84(3):268-77. PubMed ID: 22580047
[TBL] [Abstract][Full Text] [Related]
4. [Effects of LCL161, a Smac mimetic on the proliferation and apoptosis in hepatocellular carcinoma cells].
Ren K; Ma L; Chong D; Zhang Z; Zhou C; Liu H; Zhao S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Sep; 41(9):898-904. PubMed ID: 27640787
[TBL] [Abstract][Full Text] [Related]
5. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells.
Chun E; Lee KY
Biochem Biophys Res Commun; 2004 Mar; 315(3):771-9. PubMed ID: 14975768
[TBL] [Abstract][Full Text] [Related]
7. 5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma.
Hu XY; Liang JY; Guo XJ; Liu L; Guo YB
Clin Exp Pharmacol Physiol; 2015 Feb; 42(2):146-53. PubMed ID: 25363523
[TBL] [Abstract][Full Text] [Related]
8. Total alkaloids of Rubus aleaefolius Poir inhibit hepatocellular carcinoma growth in vivo and in vitro via activation of mitochondrial-dependent apoptosis.
Zhao J; Chen X; Lin W; Wu G; Zhuang Q; Zhong X; Hong Z; Peng J
Int J Oncol; 2013 Mar; 42(3):971-8. PubMed ID: 23338043
[TBL] [Abstract][Full Text] [Related]
9. Swainsonine inhibits growth and potentiates the cytotoxic effect of paclitaxel in hepatocellular carcinoma in vitro and in vivo.
You N; Liu W; Wang T; Ji R; Wang X; Gong Z; Dou K; Tao K
Oncol Rep; 2012 Dec; 28(6):2091-100. PubMed ID: 22993037
[TBL] [Abstract][Full Text] [Related]
10. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
Morisaki T; Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M
Anticancer Res; 2013 Apr; 33(4):1387-95. PubMed ID: 23564777
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus vector expressing mda-7 selectively kills hepatocellular carcinoma cell line Hep3B.
Xue XB; Chen K; Wang CJ; Zheng JW; Yu Y; Peng ZH; Wu ZD
Hepatobiliary Pancreat Dis Int; 2008 Oct; 7(5):509-14. PubMed ID: 18842498
[TBL] [Abstract][Full Text] [Related]
12. The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.
Leng AM; Liu T; Yang J; Cui JF; Li XH; Zhu YN; Xiong T; Zhang G; Chen Y
Cell Biol Int; 2012 Oct; 36(10):893-9. PubMed ID: 22694478
[TBL] [Abstract][Full Text] [Related]
13. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
14. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
[TBL] [Abstract][Full Text] [Related]
15. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumoral activity and induction of apoptosis by novel pan Bcl-2 proteins inhibitor apogossypolone with adriamycin in human hepatocellular carcinoma.
Mi JX; Wang GF; Wang HB; Sun XQ; Ni XY; Zhang XW; Tang JM; Yang DJ
Acta Pharmacol Sin; 2008 Dec; 29(12):1467-77. PubMed ID: 19026166
[TBL] [Abstract][Full Text] [Related]
17. The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha.
Oie S; Ono M; Yano H; Maruyama Y; Terada T; Yamada Y; Ueno T; Kojiro M; Hirano K; Kuwano M
Int J Oncol; 2006 Dec; 29(6):1469-78. PubMed ID: 17088986
[TBL] [Abstract][Full Text] [Related]
18. Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells.
Li X; Zhu Y; He H; Lou L; Ye W; Chen Y; Wang J
Biochem Biophys Res Commun; 2013 Jun; 436(2):259-64. PubMed ID: 23726914
[TBL] [Abstract][Full Text] [Related]
19. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
[TBL] [Abstract][Full Text] [Related]
20. Melatonin overcomes apoptosis resistance in human hepatocellular carcinoma by targeting survivin and XIAP.
Fan L; Sun G; Ma T; Zhong F; Wei W
J Pineal Res; 2013 Sep; 55(2):174-83. PubMed ID: 23679681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
